# Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period

> **NCT07017439** · PHASE3 · NOT_YET_RECRUITING · sponsor: **University of Manitoba** · enrollment: 50 (estimated)

## Conditions studied

- Benign Prostate Hypertrophy(BPH)

## Interventions

- **DRUG:** Beta-3 agonists (Mirabegron/Myrbetriq)
- **OTHER:** Placebo group post rezum

## Key facts

- **NCT ID:** NCT07017439
- **Lead sponsor:** University of Manitoba
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2025-12
- **Final completion:** 2026-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07017439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07017439, "Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT07017439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*